Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy

Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00911911

Acronym

SPAM

Enrollment

Registered

2009-06-03

Start date

2007-02-22

Completion date

2012-01-16

Last updated

2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer, Neo-adjuvant chemotherapy, Proteomic, Histological response

Brief summary

The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.

Interventions

PROCEDUREBlood sampling

Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy

PROCEDUREBIOPSY

Biopsy at the moment of inclusion, before neoadjuvant chemotherapy

PROCEDURESURGERY

Surgery after neoadjuvant chemotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women aged more than 18 years * Histologically proven breast carcinoma * Neo-adjuvant chemotherapy with anthracyclines and/or taxanes * No prior chemotherapy * Written informed consent

Exclusion criteria

* Metastatic disease

Design outcomes

Primary

Measure	Time frame
Proteomic analysis by SELDI-TOF on the tumor biopsy and blood samples Histological response according To Chevallier and Sataloff	6 months

Secondary

Measure	Time frame
Correlation with node invasion	6 months
Correlation with basal, luminal phenotypes, HER2 status or hormonal status	6 months
Correlation with the response measured by ultrasound after chemotherapy	After 3 and 5 months

Countries

France

Contacts

PRINCIPAL_INVESTIGATORBONNETERRE Jacques, MD, PhD

Centre Oscar Lambret

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026